Идёт набор NCT06807502

Evaluation of Circulating Tumor Cells (CTC) Relevance in Breast Cancer Follow-up Using the ScreenCell Device

Без фазы С лечением Breast Cancer, Metastatic Breast Cancer Invasive Breast Cancer Early Stage Breast Cancer (Stage 1-3)

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают: В протоколе указаны: The DM/DIV ScreenCell is the experimental product studied during this research.
Кому может быть актуально: Состояния в реестре: Breast Cancer, Metastatic, Breast Cancer Invasive, Breast Cancer Early Stage Breast Cancer (Stage 1-3). Базовые параметры: от 18 лет · Женщины.
Что важно проверить: Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится: Франция
Следующий шаг: Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →

Не всё понятно в терминах? Прочитайте наш гид для пациентов →

Обзор

Liquid biopsy is a noninvasive method for detecting and quantifying circulating tumor cells (CTCs). Thanks to ScreenCell technology, this study aims to evaluate the evolution of the number of CTCs during breast cancer follow-up. The identification and characterization of CTCs would make it possible to obtain information on the stage and molecular characteristics of cancer during follow-up

Вмешательства

Устройство The DM/DIV ScreenCell is the experimental product studied during this research
The product is not used directly on the subject, but on a blood sample taken from the participant.

Первичные конечные точки

Evolution of the kinetics of CTC during treatment [Срок оценки: From enrollement to the end of follow up at 9 months]

Вторичные конечные точки (1)

Molecular characterisation of CTC [Срок оценки: From enrollement to the end of follow up at 9 months]

Критерии участия

Критерии включения

For all participants :

Female with age greater than or equal to 18 years

For participants with metastatic breast cancer:

\- Patient observed with metastatic breast cancer from the outset or metastatic fall from previously treated breast cancer with change of therapeutic line at the time of inclusion.

For participants with non-metastatic invasive breast cancer:

\- Patient observed with non-metastatic infiltrative breast cancer who had not received any treatment at the time of inclusion (naïve to any treatment)

For healthy volunteers:

Participant free of any cancer at the time of inclusion, confirmed using a mammogram whose results must be satisfactory, done at the latest two years before inclusion
Participant with no history of cancer

Критерии исключения

For all participants:

Male
Age less than 18 years old
Refusal to participate or withdrawal of consent
Pregnant and/or breastfeeding women
Discovery of a cancerous pathology (other than breast cancer for patients) during participant follow-up.

For healthy volunteers: